24HourWire

24HourWire

News from all angles

MedPage Today Center

FDA Adds Another Player in ALK-Positive Lung Cancer

(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), ma…

Redirecting to MedPage Today in 3 seconds...

Read Now → Explore 24HourWire

Share this story with your network